Century Therapeutics Inc
Veridion Score
Composite trend over time
Why is IPSC moving today?
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IPSC.
IPSC insider activity
Century Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$301K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | 2026-06-12 | Russotti Gregory | Insider | sell | $2.23 | 2,584 | 512,319 | $6K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | Carr Douglas | Insider | sell | $2.23 | 1,654 | 505,094 | $4K | SEC Form 4 |
| 2026-06-15 | 2026-06-11 | Cowan Chad | Insider | sell | $2.24 | 358 | 1,175,322 | $802 | SEC Form 4 |
| 2026-06-15 | 2026-06-11 | Pfeiffenberger Brent | Insider | sell | $2.24 | 13,849 | 3,665,474 | $31K | SEC Form 4 |
| 2026-06-09 | 2026-06-08 | Russotti Gregory | Insider | sell | $2.11 | 524 | 514,903 | $1K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 28 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moIPSC contract awards, year to date.
Public federal awards linked to this ticker.
IPSC lobbying filings, year to date.
Registered lobbying filings matched to Century Therapeutics Inc.